153 related articles for article (PubMed ID: 23421613)
1. Mark-specific hazard ratio model with multivariate continuous marks: an application to vaccine efficacy.
Juraska M; Gilbert PB
Biometrics; 2013 Jun; 69(2):328-37. PubMed ID: 23421613
[TBL] [Abstract][Full Text] [Related]
2. Mark-specific hazard ratio model with missing multivariate marks.
Juraska M; Gilbert PB
Lifetime Data Anal; 2016 Oct; 22(4):606-25. PubMed ID: 26511033
[TBL] [Abstract][Full Text] [Related]
3. The 2-sample problem for failure rates depending on a continuous mark: an application to vaccine efficacy.
Gilbert PB; McKeague IW; Sun Y
Biostatistics; 2008 Apr; 9(2):263-76. PubMed ID: 17704528
[TBL] [Abstract][Full Text] [Related]
4. Mark-specific proportional hazards model with multivariate continuous marks and its application to HIV vaccine efficacy trials.
Sun Y; Li M; Gilbert PB
Biostatistics; 2013 Jan; 14(1):60-74. PubMed ID: 22764174
[TBL] [Abstract][Full Text] [Related]
5. Hypothesis tests for stratified mark-specific proportional hazards models with missing covariates, with application to HIV vaccine efficacy trials.
Sun Y; Qi L; Yang G; Gilbert PB
Biom J; 2018 May; 60(3):516-536. PubMed ID: 29488249
[TBL] [Abstract][Full Text] [Related]
6. Estimation of Stratified Mark-Specific Proportional Hazards Models with Missing Marks.
Sun Y; Gilbert PB
Scand Stat Theory Appl; 2012 Mar; 39(1):34-52. PubMed ID: 23519918
[TBL] [Abstract][Full Text] [Related]
7. Mark-specific additive hazards regression with continuous marks.
Han D; Sun L; Sun Y; Qi L
Lifetime Data Anal; 2017 Jul; 23(3):467-494. PubMed ID: 27170333
[TBL] [Abstract][Full Text] [Related]
8. Sensitivity analysis for the assessment of causal vaccine effects on viral load in HIV vaccine trials.
Gilbert PB; Bosch RJ; Hudgens MG
Biometrics; 2003 Sep; 59(3):531-41. PubMed ID: 14601754
[TBL] [Abstract][Full Text] [Related]
9. Sensitivity analyses comparing outcomes only existing in a subset selected post-randomization, conditional on covariates, with application to HIV vaccine trials.
Shepherd BE; Gilbert PB; Jemiai Y; Rotnitzky A
Biometrics; 2006 Jun; 62(2):332-42. PubMed ID: 16918897
[TBL] [Abstract][Full Text] [Related]
10. Nonparametric estimation of the joint distribution of a survival time subject to interval censoring and a continuous mark variable.
Hudgens MG; Maathuis MH; Gilbert PB
Biometrics; 2007 Jun; 63(2):372-80. PubMed ID: 17688489
[TBL] [Abstract][Full Text] [Related]
11. Inferences on relative failure rates in stratified mark-specific proportional hazards models with missing marks, with application to HIV vaccine efficacy trials.
Gilbert PB; Sun Y
J R Stat Soc Ser C Appl Stat; 2015 Jan; 64(1):49-73. PubMed ID: 25641990
[TBL] [Abstract][Full Text] [Related]
12. Semiparametric methods for multiple exposure mismeasurement and a bivariate outcome in HIV vaccine trials.
Golm GT; Halloran ME; Longini IM
Biometrics; 1999 Mar; 55(1):94-101. PubMed ID: 11318183
[TBL] [Abstract][Full Text] [Related]
13. Statistical methods for assessing differential vaccine protection against human immunodeficiency virus types.
Gilbert PB; Self SG; Ashby MA
Biometrics; 1998 Sep; 54(3):799-814. PubMed ID: 9750238
[TBL] [Abstract][Full Text] [Related]
14. Incorporating founder virus information in vaccine field trials.
Follmann D; Huang CY
Biometrics; 2015 Jun; 71(2):386-96. PubMed ID: 25773491
[TBL] [Abstract][Full Text] [Related]
15. Case-only method for cause-specific hazards models with application to assessing differential vaccine efficacy by viral and host genetics.
Dai JY; Li SS; Gilbert PB
Biostatistics; 2014 Jan; 15(1):196-203. PubMed ID: 23813283
[TBL] [Abstract][Full Text] [Related]
16. Failure time analysis of HIV vaccine effects on viral load and antiretroviral therapy initiation.
Gilbert PB; Sun Y
Biostatistics; 2005 Jul; 6(3):374-94. PubMed ID: 15831584
[TBL] [Abstract][Full Text] [Related]
17. Comparison of competing risks failure time methods and time-independent methods for assessing strain variations in vaccine protection.
Gilbert PB
Stat Med; 2000 Nov; 19(22):3065-86. PubMed ID: 11113943
[TBL] [Abstract][Full Text] [Related]
18. Augmented designs to assess immune response in vaccine trials.
Follmann D
Biometrics; 2006 Dec; 62(4):1161-9. PubMed ID: 17156291
[TBL] [Abstract][Full Text] [Related]
19. Weighted likelihood method for grouped survival data in case-cohort studies with application to HIV vaccine trials.
Li Z; Gilbert P; Nan B
Biometrics; 2008 Dec; 64(4):1247-55. PubMed ID: 19032178
[TBL] [Abstract][Full Text] [Related]
20. A comparison of eight methods for the dual-endpoint evaluation of efficacy in a proof-of-concept HIV vaccine trial.
Mehrotra DV; Li X; Gilbert PB
Biometrics; 2006 Sep; 62(3):893-900. PubMed ID: 16984333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
